Relationship between IL-10 and tumor markers in breast cancer patients

Llanes-Fernández, Leticia; Álvarez-Goyanes, Rosa Irene; Arango-Prado, Maria del Carmen; Alcocer‐González, Juan Manuel; Mojarrieta, Julia Cruz; Pérez, Xiomara Escobar; Lopez, M; Odio, Sonia Franco; Camacho-Rodríguez, Rolando; Guerra-Yi, Marta Elena; Madrid‐Marina, Vicente; Taméz-Guerra, Reyes; Rodríguez‐Padilla, Cristina

doi:10.1016/j.breast.2005.09.012

Cited by 49 publications

(55 citation statements)

References 25 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…These targeted therapies have improved the prognosis in these group of patients, however, in absence of targeted therapy, HER2 over expressing tumours are associated with worse prognosis [23,24]. Our findings of positive association of IL10 expression with higher grade and HER2 + ve tumours also supports the theory that IL10 expressing tumours are aggressive tumours [9,10].…”

Section: Follow Upsupporting

confidence: 80%

“…60 % of our breast cancer patients expressed IL10. Strategies to neutralise IL10 in the tumour microenvironment might have the potential for targeted therapy [9,20]. However, the complex role of IL10 in cancer initiation and progression makes its therapeutic potential debatable [6,18].…”

Section: Follow Upmentioning

confidence: 99%

“…Lianes -Fernandez et al noted statistically significant correlation of IL 10 expression in breast tissue with apoptotic marker Bax. The author suggested that IL10 might be an anti-apoptotic factor; its expression along with high expression of Bcl2 family protein in the tumour micro-environment, might reflect the aggressiveness of the tumour [9]. Chavey et al found no correlation of IL10 expression with patient's age, tumour size, histological type, lymph node and HER2 status of the tumour.…”

Section: Follow Upmentioning

confidence: 99%

“…A few studies have documented IL10 expression in breast cancer [8][9][10][11]. Serum IL10 concentration is raised in breast cancer patients compared to normal healthy females [12], while other failed to show any association between breast cancer and serum IL10 concentration [13].…”

Section: Introductionmentioning

confidence: 99%

“…Serum IL10 concentration is raised in breast cancer patients compared to normal healthy females [12], while other failed to show any association between breast cancer and serum IL10 concentration [13]. IL10 expressing tumours are often ER-ve and associated with apoptotic marker Bax, suggesting a possible aggressive behaviour of IL 10 expressing tumours [9,10].…”

Section: Introductionmentioning

confidence: 99%

See 4 more Smart Citations

Is Interleukin 10 (IL10) Expression in Breast Cancer a Marker of Poor Prognosis?

Bhattacharjee

Bansal

Nepal

et al. 2016

Indian J Surg Oncol

View full text Add to dashboard Cite

Interleukin 10 (IL10) is a poor prognostic marker in several cancers. Its role in breast cancer is not well elucidated. The present study is designed to see the expression of IL10 in breast cancer tissue and to evaluate its correlation with the established markers of prognosis. Sixty female patients who underwent surgery for breast cancer were enrolled for the study. Immediately after surgery, 2-5 g of tumour tissue and similar volume of peritumoural normal breast tissue were collected for IL10 assay. IL10 expression was assayed by immunohistochemistry. IL10 expressing tumours and IL10 non expressing tumours were compared. Chi square/Fisher exact test and student's t test were used to compare the data. p-valueless than 0.05 was considered as statistically significant. Thirty six patients (60 %) of carcinoma breast showed IL 10 expression in tumour tissue as compared to no IL 10 expression in any peritumouralnormal breast tissue (p < 0.01). IL10 expression had statistically significant correlation with locally advanced disease, tumour grade, HER2 + ve tumours and ER-ve, PR-ve, HER2 + ve breast cancer subtypes (p = 0.001, 0.001, 0.001 and 0.01 respectively). No correlation could be found with patient's age, tumour size, tumour histology and ER and PR status. Correlation of IL10 expressing tumours with several established poor prognostic markers of breast cancer may indicate the possible association of IL10 expression with poor prognosis. Large studies with long term follow up are needed to substantiate the association of IL10 with poor prognosis.

show abstract

Section: Follow Upsupporting

confidence: 80%

Section: Follow Upmentioning

confidence: 99%

Section: Follow Upmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 3 more Smart Citations

Is Interleukin 10 (IL10) Expression in Breast Cancer a Marker of Poor Prognosis?

Bhattacharjee

Bansal

Nepal

et al. 2016

Indian J Surg Oncol

View full text Add to dashboard Cite

show abstract

Constitutive activation of STAT3 in breast cancer cells: A review

Banerjee

Resat

2015

Intl Journal of Cancer

511

394

View full text Add to dashboard Cite

Signal transducer and activator of transcription 3 (STAT3) is constitutively activated in numerous cancer types, including more than 40% of breast cancers. In contrast to tight regulation of STAT3 as a latent transcription factor in normal cells, its signaling in breast cancer oncogenesis is multifaceted. Signaling through the IL6/JAK/STAT3 pathway initiated by the binding of IL6 family of cytokines (i.e., IL-6, IL-11) to their receptors have been implicated in breast cancer development. Receptors with intrinsic kinase activity such as EGFR and VEGFR directly or indirectly induce STAT3 activation in various breast cancer types. Aberrant STAT3 signaling promotes breast tumor progression through deregulation of the expression of downstream target genes which control proliferation (Bcl-2, Bcl-xL, Survivin, Cyclin D1, c-Myc, Mcl-1), angiogenesis (Hif1α, VEGF), and epithelial-mesenchymal transition (Vimentin, TWIST, MMP-9, MMP-7). These multiple modes of STAT3 regulation therefore make it a central linking point for a multitude of signaling processes. Extensive efforts to target STAT3 activation in breast cancer had no remarkable success in the past because the highly-interconnected nature of STAT3 signaling introduces lack of selectivity in pathway identification for STAT3 targeted molecular therapies or because its role in tumorigenesis may not be as critical as it was thought. This review provides a full spectrum of STAT3’s involvement in breast cancer by consolidating the knowledge about its role in breast cancer development at multiple levels: its differential regulation by different receptor signaling pathways, its downstream target genes, and modification of its transcriptional activity by its co-regulatory transcription factors.

show abstract

Low BMI is correlated with increased TGF‐β and IL‐10 mRNA levels in the peripheral blood of breast cancer patients

et al. 2018

View full text Add to dashboard Cite

Transforming growth factor-β (TGF-β), interleukin-10 (IL-10), and forkhead box P3 (Foxp3) have important roles in breast cancer development. Previous studies confirmed a correlation between these immune molecules and tumor characteristics, but their association with nutritional status in breast cancer is largely unknown. We aimed to investigate the association between body mass index (BMI), hemoglobin, total protein, albumin, globulin (GLB), albumin/GLB ratio (AGR), pre-albumin, prognostic nutritional index, and TGF-β, IL-10, and Foxp3 mRNA expression in patients with breast cancer. Quantitative real-time PCR was used to detect the mRNA expression of TGF-β, IL-10, and Foxp3 in the peripheral blood of 107 patients with breast cancer and 21 healthy controls. We found that TGF-β mRNA levels were 2.6-fold, 3.2-fold, and 2.3-fold higher in patients with low BMI (<23), low AGR, and high GLB, respectively, than in their counterparts (P < 0.05). In addition, IL-10 mRNA expression levels in patients with normal BMI (<23) were 2.8-fold and 3.5-fold higher than in those who were overweight (23≤ BMI <25) and obese (BMI ≥ 25), respectively (P < 0.05). In addition, TGF-β, IL-10, and Foxp3 mRNA levels were significantly higher in patients with breast cancer than in healthy controls (P < 0.05). In summary, our results suggest that nutritional status, especially BMI, may strongly affect systematic immune function in patients with breast cancer. © 2018 IUBMB Life, 70(3):237-245, 2018.

show abstract

Relationship between IL-10 and tumor markers in breast cancer patients

Cited by 49 publications

References 25 publications

Is Interleukin 10 (IL10) Expression in Breast Cancer a Marker of Poor Prognosis?

Is Interleukin 10 (IL10) Expression in Breast Cancer a Marker of Poor Prognosis?

Constitutive activation of STAT3 in breast cancer cells: A review

Low BMI is correlated with increased TGF‐β and IL‐10 mRNA levels in the peripheral blood of breast cancer patients

Contact Info

Product

Resources

About